| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BEAM | Common Stock | Sale | -$11.9K | -502 | -0.72% | $23.76 | 69.6K | Jul 1, 2024 | Direct | F1, F2 |
| transaction | BEAM | Common Stock | Sale | -$17.2K | -748 | -1.08% | $22.95 | 68.8K | Jul 2, 2024 | Direct | F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. |
| F2 | This reflects a correction to the previously reported amount of securities beneficially owned. Prior to the reported transaction, the Reporting Person beneficially owned 70,055 shares of common stock, not 70,060 shares. |
| F3 | These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. |